Members of the life sciences industry now face a new era of global transparency. The latest rules from the European Federation of Pharmaceutical Industries and Associations (EFPIA), provide yet another example of this trend. The EFPIA Disclosure Code requires that calendar year 2015 transfers of value be reported starting in 2016. Companies need to begin working immediately to address these new requirements.
To meet the challenge, decision makers need to determine the best strategy for their teams. Key decisions include:
- Build or Buy
- Integrate multiple systems or Accelerate into one system
- Undertake legacy data matching or Start with new data
- Report from multiple sources or Report from a single platform
The White Paper below offers a new perspective on the key decisions outlined above and offers a strategic alternative on how to best meet industry transparency disclosure requirements: